Olema Pharmaceuticals Inc
OLMA
NASDAQ
Biotechnology
$10.63
USD
+0.12 (+1.14%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $919.60M
Volume 1.2M
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-185.15M
TTM
-43.6%
YoY
Operating Cash Flow
$-148.72M
TTM
-19.1%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 4.2 | 4.0 | 5.9 | 6.9 | 8.8 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 34.9 | 47.9 | 45.9 | 50.1 | 58.0 |
Operating Income | -34.9 | -47.9 | -45.9 | -50.1 | -58.0 |
EBITDA | -34.7 | -47.7 | -45.8 | -49.9 | -57.9 |
Other Income / Expense | -0.0 | 0.0 | 0.0 | 0.0 | 0.1 |
Total Other Income / Expense | 4.5 | 4.1 | 3.7 | 4.0 | 4.9 |
Income Before Income Taxes | -30.4 | -43.8 | -42.2 | -46.1 | -53.1 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -30.4 | -43.8 | -42.2 | -46.1 | -53.1 |
Consolidated Net Income / Loss | -30.4 | -43.8 | -42.2 | -46.1 | -53.1 |
Net Income Attributable to Common Shareholders | -30.4 | -43.8 | -42.2 | -46.1 | -53.1 |
Basic EPS | -$0.36 | -$0.51 | -$0.49 | -$0.50 | -$0.52 |
Diluted EPS | -$0.36 | -$0.51 | -$0.49 | -$0.50 | -$0.52 |
Basic Shares Outstanding | 85.4M | 85.5M | 85.7M | 91.4M | 102.8M |
Diluted Shares Outstanding | 85.4M | 85.5M | 85.7M | 91.4M | 102.8M |